KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Accured Expenses: 2018-2025

Historic Change in Accured Expenses for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to $21.2 million.

  • Esperion Therapeutics' Change in Accured Expenses rose 63.22% to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.9 million, marking a year-over-year increase of 23.08%. This contributed to the annual value of $18.3 million for FY2024, which is 16.99% down from last year.
  • As of Q3 2025, Esperion Therapeutics' Change in Accured Expenses stood at $21.2 million, which was up 1,311.84% from -$1.7 million recorded in Q2 2025.
  • Esperion Therapeutics' Change in Accured Expenses' 5-year high stood at $25.0 million during Q1 2021, with a 5-year trough of -$21.8 million in Q2 2021.
  • Its 3-year average for Change in Accured Expenses is $5.4 million, with a median of $4.6 million in 2023.
  • In the last 5 years, Esperion Therapeutics' Change in Accured Expenses slumped by 394.93% in 2021 and then skyrocketed by 690.34% in 2023.
  • Esperion Therapeutics' Change in Accured Expenses (Quarterly) stood at -$789,000 in 2021, then soared by 255.77% to $1.2 million in 2022, then soared by 566.80% to $8.2 million in 2023, then dropped by 22.55% to $6.3 million in 2024, then soared by 63.22% to $21.2 million in 2025.
  • Its Change in Accured Expenses was $21.2 million in Q3 2025, compared to -$1.7 million in Q2 2025 and -$932,000 in Q1 2025.